BIOPHARMA
By
Can Pfizer’s 2025 Execution Set the Stage for Sustainable Growth in 2026?
NEW YORK, NY — As 2025 comes to a close, Pfizer Inc. reflects on a year marked by…
Will the US Health Agency Expand Coverage for GLP-1 Weight-Loss Drugs?
The U.S. Centers for Medicare & Medicaid Services (CMS) announced a new voluntary program to expand coverage of…
How is Bristol Myers Squibb Driving Growth After 2025’s Strategic Recalibration?
Bristol Myers Squibb (BMS) continues to build momentum in its post-loss-of-exclusivity strategy, with 2025 marked as a year…
Will Agios Pharma’s FDA Approval Expansion Drive a New Growth Phase in Blood Disorder Treatment?
Cambridge, Massachusetts | December 26, 2025 Agios Pharmaceuticals announced a major regulatory milestone after the U.S. Food and…
Can Eli Lilly’s 2025 Brand Launches and Label Expansions Redefine Leadership in Metabolic, Oncology, and Neuroscience Markets Beyond 2026?
Global | January 2026 — Eli Lilly and Company accelerated its transformation in 2025 through a series of…
Can Pfizer’s 2025 Brand Launches Across Vaccines, Oncology, and Specialty Care Reshape Its Growth Trajectory Beyond 2026?
Global | January 2026 — Pfizer Inc. advanced its post-pandemic transformation in 2025 through a series of targeted…
